Stock BDTX BLACK DIAMOND THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
4.65 USD -3.39% Intraday chart for Black Diamond Therapeutics, Inc. -2.11% +65.48%
Jun. 01 Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting CI
May. 16 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating
MT
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating
MT
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target
MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2
MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11
MT
Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3
MT
Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating
MT
Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating
MT
Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22
MT
HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy
MT
Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating
MT
BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target
MT
BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating
MT
BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating
MT
BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48
MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48
MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating
MT
BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target
MT
BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BDTX Stock
  4. News Black Diamond Therapeutics, Inc.
  5. Analyst Reco.